From: reuters.com Puma Biotechnology Inc on Friday won a key recommendation from a European Medicines Agency panel on its lead breast cancer drug, five months after the regulator recommended against approving it. Shares of Puma, which on Tuesday signaled the committee was likely to give positive opinion on the drug, neratinib, was up over 5 percent in light pre-market trading …
-
-
The True Meaning of Easter
-
Peace for a Breast Cancer Survivor
-
What Would Motivate a Person to Action After a Breast Cancer Diagnosis
-
What’s on the Outside Doesn’t Really Matter to Many Breast Cancer Survivors
-
From a Breast Cancer Survivor: A Message to Telephone and Telemarketer Solicitors
